Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,182 across all filing types
Latest filing 2021-09-19 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
U.S.FDA inspection of Lupin's Goa (India) facility.
Regulatory Filings Classification · 95% confidence The document is a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, regarding a U.S. FDA inspection of Lupin's facility. It is a regulatory announcement about an event (inspection and observations) rather than a financial report, management change, or other specific filing type. The document is short (1629 characters) and serves as a regulatory update. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other categories.
2021-09-19 English
Updates
Regulatory Filings Classification · 95% confidence The document is a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, regarding a U.S. FDA inspection of a facility. It is addressed to stock exchanges and provides information about the inspection and observations. The document is short (1630 characters) and serves as a regulatory announcement rather than a detailed report or financial statement. It does not contain financial data, management discussion, or detailed report content. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-09-19 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is very short (416 characters) and contains a table detailing the loss of share certificates under Regulation 39(3). This is a specific regulatory disclosure related to share certificates, not a financial report or management information. It does not contain financial data, management discussion, or voting results. It is a regulatory announcement related to shareholding documentation. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory disclosures that do not fit other categories.
2021-09-17 English
Intimation of Loss of Share Certificate by the Shareholder.
Regulatory Filings Classification · 95% confidence The document is an intimation under Regulation 39(3) of SEBI (Listing Obligation and Disclosure Requirements), 2015, regarding details of loss of share certificates and stop transfer requests. It is addressed to the stock exchange and contains no financial data or report content. The document is a regulatory announcement related to share certificate status, not a financial report or earnings release. It fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2021-09-17 English
Updates
Legal Proceedings Report Classification · 95% confidence The document is a letter addressed to stock exchanges disclosing a settlement agreement related to ongoing legal proceedings involving the company. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events. The content focuses on legal proceedings and settlement amounts, with no financial statements or detailed financial analysis. The document is relatively short (2837 characters) and serves as an announcement of a legal matter rather than a full legal report or audit. Therefore, it fits best under Legal Proceedings Report (LTR).
2021-09-15 English
Settlement of litigation in Glumetza® matter.
Legal Proceedings Report Classification · 95% confidence The document is a disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to regulatory announcements by listed companies. It discusses a legal settlement related to antitrust class actions involving the company. The content is an announcement of a legal proceeding update and settlement approval by the Board of Directors. The document is relatively short (2875 characters) and serves as an official notification to stock exchanges rather than a detailed legal report or financial statement. Therefore, it fits best under the category of Legal Proceedings Report (LTR).
2021-09-15 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.